Open for inclusion

Phase II study of carfilzomib-cyclophophamide-dexamethasone and high-dose melphalan followed by randomization between observation or maintenance with carfilzomib and dexamethasone in patients with relapsed multiple myeloma after high-dose melphalan with

Cancer type: Myeloma

Phase: II

Principal Investigator: Andersen Niels Frost

Country: DK

Keywords: Denmark, Aarhus

Status: Open for inclusion

Link to Clinicaltrials.gov: EudraCT no. 2013-003789-15